Literature DB >> 14500399

Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.

Aude Bonehill1, Carlo Heirman, Sandra Tuyaerts, Annelies Michiels, Yi Zhang, Pierre van der Bruggen, Kris Thielemans.   

Abstract

For the induction of an optimal immune response against cancer or infections not only CD8(+) CTLs but also CD4(+) T helper cells must be induced, in particular IFN-gamma-secreting type 1 T helper cells. Several strategies have been explored to target tumor-associated antigens to the HLA class II processing compartments. We engineered a genetic construct encoding an invariant chain (Ii) protein where the CLIP region has been replaced by sequences encoding HLA class II-restricted MAGE-A3 epitopes. Monocyte-derived dendritic cells (DCs) were electroporated with in vitro transcribed mRNA encoding a modified Ii protein containing the HLA-DP4-restricted MAGE-A3 epitope. The capacity of these electroporated DCs to stimulate a MAGE-A3-specific T-cell clone was compared at different stages of DC maturation with the T-cell stimulatory capacity of DCs pulsed with the synthetic peptide. After electroporation, the T-cell stimulatory capacity was shown to be high and long lasting, whereas the stimulatory capacity of peptide-pulsed DCs decreased rapidly. Upon coculture with epitope-specific T cells, electroporated immature DCs expressed enhanced levels of costimulatory molecules, HLA class II molecules, and CD83, suggesting the induction of maturation. The electroporated DCs can be frozen and thawed without losing their capability to stimulate the specific T-cell clone in vitro, and they are able to stimulate unprimed CD4(+) T cells specific to the HLA-DP4-restricted MAGE-A3 epitope in vitro. Similar results were obtained with a recombinant Ii containing the MAGE-A3 epitope presented in the context of HLA-DR13.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500399

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells.

Authors:  Junbao Yang; Laurel Huston; Deanna Berger; Nancy A Danke; Andrew W Liu; Mary L Disis; William W Kwok
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

Review 2.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 3.  Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Transl Med       Date:  2012-07-31       Impact factor: 5.531

Review 4.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Authors:  Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

5.  Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly.

Authors:  Mark Anczurowski; Yuki Yamashita; Munehide Nakatsugawa; Toshiki Ochi; Yuki Kagoya; Tingxi Guo; Chung-Hsi Wang; Muhammed A Rahman; Kayoko Saso; Marcus O Butler; Naoto Hirano
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

Review 6.  Self-assembled mRNA vaccines.

Authors:  Jeonghwan Kim; Yulia Eygeris; Mohit Gupta; Gaurav Sahay
Journal:  Adv Drug Deliv Rev       Date:  2021-01-02       Impact factor: 17.873

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.